Retatrutide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications

Introduction

Retatrutide is still in Phase 3 testing. Eli Lilly’s TRIUMPH program ran enrollment through 2024 with topline data expected in 2026. That means current eligibility criteria come from the trials themselves rather than an FDA label. The trial inclusion rules tell you who Lilly thought would benefit most, and the exclusion rules tell you who the company wanted to keep away from a triple agonist with glucagon activity.

Once retatrutide reaches market, the FDA label will likely mirror semaglutide and tirzepatide eligibility for chronic weight management. That means BMI 30 or higher, or BMI 27 with a comorbidity. The contraindications will almost certainly include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2, the same boxed warning every GLP-1 carries.

This article walks through trial eligibility, expected label eligibility, and the conditions that should make you pause. TrimRx offers personalized treatment plans for currently approved GLP-1 medications while retatrutide moves through approval.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Who Qualifies for Retatrutide Based on the Trial Criteria?

The TRIUMPH-1 obesity trial enrolled adults aged 18 and older with body mass index of 30 kg/m² or higher, or BMI of 27 with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. Participants had to be willing to follow a reduced-calorie diet and increased physical activity, matching standard GLP-1 obesity trial design.

Quick Answer: TRIUMPH-1 enrolled adults with BMI 30 or higher, or BMI 27 with one weight-related comorbidity (Jastreboff et al. 2023 NEJM Phase 2 used the same cutoffs)

TRIUMPH-2 enrolled adults with type 2 diabetes and obesity, requiring an A1C between 7.0 and 10.5 percent. TRIUMPH-3 focused on cardiovascular outcomes, enrolling adults with established cardiovascular disease and BMI 27 or higher. Each trial used slightly different inclusion criteria, but the BMI floors stayed consistent with the obesity treatment guidelines from the American Association of Clinical Endocrinology.

These cutoffs mirror what the FDA approved for semaglutide (Wegovy®) and tirzepatide (Zepbound®), so the eventual retatrutide label will likely look similar. If you meet criteria for Wegovy or Zepbound today, you’ll probably meet criteria for retatrutide when it launches.

What Conditions Absolutely Rule Out Retatrutide?

Three conditions exclude you outright. Personal history of medullary thyroid carcinoma. Family history of MTC in a first-degree relative. Multiple endocrine neoplasia syndrome type 2. These are the standard GLP-1 class boxed warning conditions, based on rodent C-cell tumor signals seen in preclinical work with liraglutide and carried forward to every drug in the class.

Pregnancy is also a hard contraindication. Animal reproductive toxicity studies with GLP-1 agonists have shown fetal harm at clinically relevant exposures, and there’s no human safety data. TRIUMPH excluded pregnant or breastfeeding women and required reliable contraception in women of childbearing potential.

Active pancreatitis is the fourth absolute exclusion. GLP-1 agonists have been associated with acute pancreatitis in postmarketing reports, though large randomized data has not shown a clear increase in incidence. If you’ve ever had pancreatitis, you and your prescriber need to weigh the trade-off carefully.

Does Diabetes Status Affect Retatrutide Eligibility?

Type 2 diabetes is not a contraindication, it’s actually one of the studied populations. TRIUMPH-2 enrolled adults with T2D and showed 17.5 percent placebo-adjusted weight loss at 48 weeks plus A1C reductions exceeding 2 percent on the high dose. Diabetes plus obesity is the textbook retatrutide candidate.

Type 1 diabetes is different. The trials excluded T1D participants, and the glucagon receptor agonism creates theoretical concern about insulin balance in patients without endogenous insulin production. T1D patients should not expect retatrutide to be approved or prescribed for them in the near term.

Brittle glycemic control with frequent hypoglycemia is also a flag. GLP-1 plus GIP activation can drive insulin release, and patients on insulin or sulfonylureas have higher hypoglycemia risk. The TRIUMPH trials required dose reductions of background hypoglycemic agents at enrollment to manage this.

What About Cardiovascular and Kidney Conditions?

Established cardiovascular disease is a positive indicator, not a barrier. TRIUMPH-3 specifically enrolled patients with prior heart attack, stroke, or symptomatic peripheral artery disease to test cardiovascular outcomes. The SELECT trial of semaglutide (Lincoff et al. 2023 NEJM) showed 20 percent MACE reduction, and retatrutide is expected to show similar or larger effects given its weight loss magnitude.

Severe heart failure (NYHA Class IV) was excluded from Phase 2, as was unstable angina within 90 days. Stable heart failure and well-managed coronary disease were both included with cardiology clearance.

Chronic kidney disease eligibility depends on stage. eGFR below 30 mL/min/1.73m² was an exclusion in TRIUMPH. Stage 1 through 3 CKD was allowed. The FLOW trial of semaglutide (Perkovic et al. 2024 NEJM) showed 24 percent reduction in kidney and cardiovascular death, so kidney benefits from triple agonism look likely but unproven.

Can Older Adults Take Retatrutide?

Yes, with monitoring. TRIUMPH-1 enrolled participants up to age 75 with no upper limit specified for Phase 3. Older adults made up roughly 20 percent of Phase 2 enrollment. Weight loss magnitudes were similar across age groups in the published data.

The concerns in older adults aren’t unique to retatrutide. Sarcopenia risk is the big one. Aggressive weight loss in adults over 65 risks muscle loss that worsens frailty and fall risk. Body composition data from SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed that lean mass loss accounted for about 25 percent of total weight loss, which is roughly proportional to what you’d expect from dietary weight loss alone.

Older adults considering retatrutide should plan for protein intake of 1.2 to 1.6 grams per kilogram body weight daily and resistance training at least twice weekly to protect muscle.

Key Takeaway: Active pancreatitis, severe gastroparesis, and pregnancy are exclusion criteria across all GLP-1 trials including TRIUMPH

What Gastrointestinal Conditions Matter?

Severe gastroparesis was an exclusion in TRIUMPH. GLP-1 drugs slow gastric emptying by design, and adding that to pre-existing gastroparesis can cause severe symptoms. Mild gastroparesis or functional dyspepsia falls into a gray zone where shared decision-making is appropriate.

Inflammatory bowel disease isn’t a formal contraindication, but the GI side effect profile of retatrutide (nausea, diarrhea, constipation) can complicate IBD management. Active flares are a reason to delay starting.

History of gallstones or cholecystectomy isn’t an exclusion. Rapid weight loss from any cause increases gallstone risk, and GLP-1-induced weight loss raises gallbladder event rates by roughly 1 to 2 percent above placebo. That’s a known trade-off, not a deal breaker.

What Medications Interact Badly with Retatrutide?

The combinations that need attention all relate to glycemic control or gastric emptying. Insulin and sulfonylureas combined with retatrutide raise hypoglycemia risk. Trial protocols required preemptive dose reductions of these agents, typically 25 to 50 percent at retatrutide initiation.

Oral medications with narrow therapeutic windows can be affected by delayed gastric emptying. Levothyroxine, warfarin, and certain seizure medications need monitoring during titration. Take levothyroxine at least 30 to 60 minutes before any food or other oral medication, which becomes more important on a GLP-1 with slowed gastric emptying.

Hormonal contraceptives are reduced in efficacy by significant gastric delay. Wegovy’s label recommends backup contraception during titration. Retatrutide’s label will almost certainly carry the same advice.

Are There Mental Health Considerations?

The TRIUMPH trials screened out patients with active suicidal ideation in the past 6 months, severe depression on the PHQ-9, or recent psychiatric hospitalization. The FDA has been monitoring GLP-1-class drugs for suicidality signals since 2023. Large pharmacovigilance reviews to date have not shown a clear causal link, but the precaution remains.

If you have a history of bipolar disorder, severe major depression, or eating disorders, retatrutide eligibility becomes a clinical conversation rather than a check-the-box exercise. Restrictive eating disorders are a particular concern because dramatic appetite suppression can worsen restriction patterns.

How Does TrimRx Evaluate Eligibility for Currently Approved GLP-1s?

While retatrutide moves through Phase 3, TrimRx offers a free assessment quiz that matches patients to compounded semaglutide or tirzepatide based on BMI, comorbidities, medication history, and contraindication screening. Licensed providers review every submission and order labs when clinically indicated.

The eligibility logic mirrors what trials use: BMI 30 or higher, or BMI 27 with comorbidity, no personal or family MTC history, no MEN2, no active pancreatitis, no pregnancy. The same framework will likely apply when retatrutide reaches the market.

Bottom line: Phase 2 enrollment excluded patients on insulin or sulfonylureas, and the Phase 3 trials maintained that pattern with rare exceptions

FAQ

When Will Retatrutide Be Available Outside Clinical Trials?

Eli Lilly is targeting FDA submission in late 2025 with potential approval in 2026 or 2027. Real-world availability for the obesity indication could come within 12 months of approval, similar to the Zepbound launch timeline.

Can I Switch From Wegovy or Zepbound to Retatrutide?

You’ll be able to once it’s available. Switching protocols are not yet published, but based on tirzepatide-to-retatrutide transition data in Phase 2, a one-week washout followed by retatrutide initiation at 2 or 4 mg is likely.

Is Retatrutide Approved for Adolescents?

No. All trials enrolled adults aged 18 and older. The semaglutide pediatric pathway took several years after adult approval, so adolescent retatrutide approval is unlikely before 2028.

Will Insurance Cover Retatrutide?

For obesity alone, expect the same coverage barriers as Wegovy and Zepbound. For type 2 diabetes, coverage is generally easier. Cardiovascular indication expansion could improve coverage further if TRIUMPH-3 shows MACE benefit.

What’s the Difference Between Retatrutide Eligibility and Tirzepatide Eligibility?

Functionally very similar. Both target BMI 30 or higher, or BMI 27 with comorbidity. Retatrutide’s glucagon receptor activity adds extra caution for severe liver disease and brittle T1D, but those conditions also exclude tirzepatide candidates in practice.

Can I Take Retatrutide If I’ve Had Bariatric Surgery?

Phase 2 included some post-bariatric patients with weight regain, and outcomes were similar to non-bariatric participants. Phase 3 protocols vary by trial. Post-bariatric eligibility on the eventual FDA label is likely without restriction.

What If I Have Multiple Exclusion Conditions?

A single relative contraindication may not block you. Multiple stacked concerns (active GI disease plus brittle diabetes plus severe CKD) usually mean retatrutide is not the right tool. Your prescriber will weigh the total picture.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.